Jennifer H. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer H. Lee has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Hedvat
NewYork‐Presbyterian Hospital Department of Pharmacy New York New York USA
5 shared publications - David M. Salerno
Department of Pharmacy NewYork‐Presbyterian Hospital New York New York USA
4 shared publications - Nicholas W. Lange
NewYork Presbyterian Hosp, Dept Pharm, New York, NY USA
4 shared publications Anastasia Anamisis
Department of Pharmacy, NewYork-Presbyterian Hospital, New York City, New York, USA
3 shared publicationsEsther C. Liu
NewYork‐Presbyterian Hospital Department of Pharmacy New York New York USA
3 shared publicationsDanielle Kovac
Department of Pharmacy NewYork‐Presbyterian Hospital New York NY USA
2 shared publications
Latest Publications
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (11) , 2682-2688
Open AccessCOVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- 15 January 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (3) , e14594
Nitazoxanide treatment for norovirus infection in solid organ transplant recipients
- 13 January 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (3) , e14213
Managing the significant drug‐drug interaction between tacrolimus and letermovir in solid organ transplant recipients
- 13 January 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (3) , e14213
Managing the significant drug‐drug interaction between tacrolimus and letermovir in solid organ transplant recipients
- Open Access
- 17 December 2020
- Published by Wiley in Clinical Transplantation
- Vol. 35 (3) , e14193
SARS‐CoV‐2 infection increases tacrolimus concentrations in solid‐organ transplant recipients
- 17 December 2020
- Published by Wiley in Clinical Transplantation
- Vol. 35 (3) , e14193
Open AccessSARS‐CoV‐2 infection increases tacrolimus concentrations in solid‐organ transplant recipients
- 22 November 2020
- Published by Wiley in Clinical Transplantation
- Vol. 35 (1) , e14148
Deceased donor renal transplantation in patients on apixaban at time of transplant surgery: A case series
- 22 November 2020
- Published by Wiley in Clinical Transplantation
- Vol. 35 (1) , e14148
Deceased donor renal transplantation in patients on apixaban at time of transplant surgery: A case series
- 29 January 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (3) , e13491
Antibiotic prophylaxis for ureteral stent removal after kidney transplantation
There are no guidelines for antibiotic prophylaxis for ureteral stent removal after kidney transplantation. We reviewed the charts of 277 adult kidney transplant recipients with ureteral stents transplanted at our center between September 2014 and December 2015 and investigated whether antibiotic prophylaxis for stent removal was associated with reduced incidence of urinary tract infections (UTI). We defined UTI as a urine culture ≥104 CFU/mL of bacterial isolates irrespective of symptoms. Primary outcome was the incidence of UTI within four weeks of stent removal. Among the 277 recipients, 199 (72%) were on sulfamethoxazole/trimethoprim (SMZ/TMP) as Pneumocystis jirovecii prophylaxis. At the time of ureteral stent removal, 56 recipients (20%) received additional antibiotic prophylaxis (ABX+) and 221 (80%) did not (ABX‐). The difference in the incidence of UTI in the ABX(+) group (16%) and ABX(−) group (19%) was not statistically significant (P = 0.85). Variables independently associated with the development of UTI were recipient age (odds ratio [OR] 1.04, [95% confidence interval 1.01‐1.07]) and UTI while stents were in situ (OR 3.9 [2.00‐7.62]). Use of SMZ/TMP was protective (OR 0.35 [0.18‐0.7]). Our study does not show a statistically significant benefit for additional antibiotic prophylaxis for ureteral stent removal. Antibiotic prophylaxis may be beneficial for recipients not on SMZ/TMP at the time of stent removal.
- 29 January 2019
- Published by Wiley in Clinical Transplantation
- Vol. 33 (3) , e13491
Antibiotic prophylaxis for ureteral stent removal after kidney transplantation
There are no guidelines for antibiotic prophylaxis for ureteral stent removal after kidney transplantation. We reviewed the charts of 277 adult kidney transplant recipients with ureteral stents transplanted at our center between September 2014 and December 2015 and investigated whether antibiotic prophylaxis for stent removal was associated with reduced incidence of urinary tract infections (UTI). We defined UTI as a urine culture ≥104 CFU/mL of bacterial isolates irrespective of symptoms. Primary outcome was the incidence of UTI within four weeks of stent removal. Among the 277 recipients, 199 (72%) were on sulfamethoxazole/trimethoprim (SMZ/TMP) as Pneumocystis jirovecii prophylaxis. At the time of ureteral stent removal, 56 recipients (20%) received additional antibiotic prophylaxis (ABX+) and 221 (80%) did not (ABX‐). The difference in the incidence of UTI in the ABX(+) group (16%) and ABX(−) group (19%) was not statistically significant (P = 0.85). Variables independently associated with the development of UTI were recipient age (odds ratio [OR] 1.04, [95% confidence interval 1.01‐1.07]) and UTI while stents were in situ (OR 3.9 [2.00‐7.62]). Use of SMZ/TMP was protective (OR 0.35 [0.18‐0.7]). Our study does not show a statistically significant benefit for additional antibiotic prophylaxis for ureteral stent removal. Antibiotic prophylaxis may be beneficial for recipients not on SMZ/TMP at the time of stent removal.